Entries by Maren Kühr

Accelerating Europe’s Biotech Revolution

As the global race for biosolutions intensifies, Europe is at a critical crossroads, and I am deeply concerned about the future of our continent’s biotech industry. While countries like China and the United States rapidly advance their biotech industries, Europe’s slow and not up-to-date regulatory system poses a significant risk to maintaining our leadership.

New CEO – new chapter

MC2 Therapeutics A/S, a Hørsholm-based pharmaceutical company focused on topical therapies in inflammatory skin conditions, announced the appointment of Trine Ahlgreen as Chief Executive Officer at the end of May.

Industry veteran appointed

Italian Sibylla Biotech has appointed a new Chairman of the Board of Directors: Dieter Weinand, former President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG.

Reinforcement for Angelini Ventures

Dr Regina Hodits joined Angelini Ventures, the VC arm of Angelini Industries, in April as the new Managing Director. She will be based in Germany and lead the company’s international biotech investment strategy with focus Biotech AI and therapeutics.

Revolutionising Oral Drug Delivery

NovoArc GmbH, an Austrian biotech startup and BIOTECH AUSTRIA member, develops lipid-based formulations to enable the oral delivery of drugs that currently require injection. Its innovative approach paves the way for more convenient and effective treatments.

Knowledge-based bioeonomy – reloaded

Biotechnology provides the necessary toolbox, ranging from energy-saving biocatalysts for the chemical industry to climate-friendly production of animal feed and food proteins for more resilience, microbial recovery of rare critical materials, to the production of pharmaceutically active ingredients.

Precision oligonucleotides for therapeutics

Therapeutic oligonucleotides are rapidly transforming drug development by enabling precise gene modulation strategies. Microsynth empowers biotech, pharmaceutical, and academic researchers with high-quality therapeutic oligonucleotides, supporting every stage from sequence design to preclinical development. With tailored solutions, advanced automation, and expert design support, we accelerate your therapeutic programmes with precision and speed.

Moss Cell Line Finds Broader Application

Freiburg-based Eleva relies on its moss-based platform for the development of new biologics both independently and with partners. A new alliance with Spanish CDMO 3PBIOVIAN now secures clinical production capacity for both activities.

Connecting Europe’s biotech community

Join YEBN’s top biotech event in Budapest! Connect with innovators, learn from professionals, and shape the future of biotech. Don’t miss this opportunity to network and grow, join us now!